Tags : C3G

Regulatory

Novartis’ Iptacopan (LNP023) Receives the US FDA’s Breakthrough Therapy Designation

Shots: The US FDA has granted BTD in paroxysmal nocturnal hemoglobinuria and RPDD in C3 glomerulopathy The BTD is based on results from two ongoing P-II studies, where iptacopan showed benefits both in patients who remained anemic and dependent on transfusions despite SOC anti-complement treatment as well as monothx. in anti-C5 naïve PNH patients Iptacopan […]Read More